Syngene International Limited Reports Audited Standalone and Consolidated Earnings Results for the Quarter and Year Ended March 31, 2018
April 25, 2018 at 08:58 am EDT
Share
Syngene International Limited reported audited standalone and consolidated earnings results for the quarter and year ended March 31, 2018. For the quarter on standalone basis, the company reported revenue from operations of INR 4,091 million against INR 2,913 million for the same period a year ago. Total income was INR 4,257 million against INR 3,152 million for the same period a year ago. Profit before exceptional items and tax was INR 1,041 million compared with INR 904 million a year ago. Profit before taxation was INR 1,041 million against INR 904 million for the same period a year ago. Net profit for the period was INR 843 million against INR 784 million for the same period a year ago. Diluted earnings per share were INR 4.24 against INR 3.95 for the same period a year ago.
For the year on standalone basis, the company reported revenue from operations of INR 14,231 million against INR 12,009 million for the same period a year ago. Total income was INR 14,849 million against INR 12,716 million for the same period a year ago. Profit before exceptional items and tax was INR 3,721 million compared with INR 3,465 million a year ago. Profit before taxation was INR 3,721 million against INR 3,465 million for the same period a year ago. Net profit for the period was INR 3,051 million against INR 2,873 million for the same period a year ago. Diluted earnings per share were INR 15.41 against INR 14.55 for the same period a year ago.
For the quarter on consolidated basis, the company reported revenue from operations of INR 4,091 million. Total income was INR 4,257 million. Profit before exceptional items and tax was INR 1,044 million. Profit before taxation was INR 1,044 million. Net profit for the period was INR 845 million. Diluted earnings per share were INR 4.25.
For the year, the company reported revenue from operations of INR 14,231 million. Total income was INR 14,849 million. Profit before exceptional items and tax was INR 3,725 million. Profit before taxation was INR 3,725 million. Net profit for the period was INR 3,054 million. Diluted earnings per share were INR 15.43.
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.
SYNGENE INTERNATIONAL LIMITED 
